Expression of PDGFRα is a Determinant of the PVR potential of ARPE19 cells

Investigative Ophthalmology and Visual Science

Volumn 52, Issue 9, 2011, Pages 5016-5021

  Lei, Hetian ^a   Rhéaume, Marc André ^b   Velez, Gisela ^a   Mukai, Shizuo ^b   Kazlauskas, Andrius ^a  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN TYPE 1; COMPLEMENTARY DNA; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN KINASE B; PROTEIN P53; SHORT HAIRPIN RNA;

ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; MUSCLE FIBER CONTRACTION; NONHUMAN; PIGMENT EPITHELIUM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; VITREORETINOPATHY; WESTERN BLOTTING; ANIMAL; CELL CULTURE; CELL DIVISION; CYTOLOGY; DISEASE MODEL; GENE EXPRESSION; GENETICS; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION; THROMBOCYTE RICH PLASMA; VITREOUS BODY;

ANIMALS; APOPTOSIS; CELL DIVISION; CELLS, CULTURED; DISEASE MODELS, ANIMAL; GENE EXPRESSION; HUMANS; PLATELET-RICH PLASMA; RABBITS; RECEPTOR, PLATELET-DERIVED GROWTH FACTOR ALPHA; RETINAL PIGMENT EPITHELIUM; SIGNAL TRANSDUCTION; VITREORETINOPATHY, PROLIFERATIVE; VITREOUS BODY;

EID: 80054776345     PISSN: 01460404     EISSN: 15525783     Source Type: Journal    
DOI: 10.1167/iovs.11-7442     Document Type: Article

References (29)

1. Ophir A, Blumenkranz MS, Claflin AJ. Experimental intraocular proliferation and neovascularization. Am J Ophthalmol. 1982;94: 450-457.
2. Sundaram V, Barsam A, Virgili G. Intravitreal low molecular weight heparin and 5-fluorouracil for the prevention of proliferative vitreoretinopathy following retinal reattachment surgery. Cochrane Database Syst Rev CD006421.
3. Leaver PK. Proliferative vitreoretinopathy. Br J Ophthalmol. 1995; 79:871-872.
4. Han D. Proliferative Vitreoretinopathy. Philadelphia: WB Saunders; 2008.
5. Charteris DG. Growth factors in proliferative vitreoretinopathy. Br J Ophthalmol. 1998;82:106.
6. Jerdan JA, Pepose JS, Michels RG, et al. Proliferative vitreoretinopathy membranes. Ophthalmology. 1989;9:801-810.
7. Baudouin C, Fredj-Reygrobellet D, Brignole F, Negre F, Lapalus P, Gastaud P. Growth factors in vitreous and subretinal fluid cells from patients with proliferative vitreoretinopathy. Ophthalmic Res. 1993;25:52-59.
8. Vinores SA, Campochiaro PA, Conway BP. Ultrastructural and electron-immunocytochemical characterization of cells in epiretinal membranes. Invest Ophthalmol Vis Sci. 1990;31:14-28.
9. Cui JZ, Chiu A, Maberley D, Ma P, Samad A, Matsubara JA. Stage specificity of novel growth factor expression during development of proliferative vitreoretinopathy. Eye. 2007;21:200-208.
10. Laqua H, Machemer R. Glial cell proliferation in retinal detachment (massive periretinal proliferation). Am J Ophthalmol. 1975;80: 602-618.
11. Campochiaro PA. Mechanisms in ophthalmic disease: pathogenic mechanisms in proliferative vitreoretinopathy. Arch Ophthalmol. 1997;115:237-241.
12. Ryan SJ. Traction retinal detachment: XLIX Edward Jackson Memorial Lecture. Am J Ophthalmol. 1993;115:1-20.
13. Lei H, Rheaume MA, Kazlauskas A. Recent developments in our understanding of how platelet-derived growth factor (PDGF) and its receptors contribute to proliferative vitreoretinopathy. Exp Eye Res. 2010;90:376-381.
14. Andrews A, Balciunaite E, Leong FL, et al. Platelet-derived growth factor plays a key role in proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1999;40:2683-2689.
15. Ikuno Y, Kazlauskas A. An in vivo gene therapy approach for experimental proliferative vitreoretinopathy using the truncated platelet-derived growth factor alpha receptor. Invest Ophthalmol Vis Sci. 2002;43:2406-2411.
16. Ikuno Y, Leong FL, Kazlauskas A. Attenuation of experimental proliferative vitreoretinopathy by inhibiting the platelet-derived growth factor receptor. Invest Ophthalmol Vis Sci. 2000;41:3107-3116.
17. Zheng Y, Ikuno Y, Ohj M, et al. Platelet-derived growth factor receptor kinase inhibitor AG1295 and inhibition of experimental proliferative vitreoretinopathy. Jpn J Ophthalmol. 2003;47:158-165.
18. Lei H, Velez G, Cui J, et al. N-acetylcysteine suppresses retinal detachment in an experimental model of proliferative vitreoretinopathy. Am J Pathol. 2010;177:132-140.
19. Campochiaro PA, Hackett SF, Vinores SA, et al. Platelet-derived growth factor is an autocrine growth stimulator in retinal pigmented epithelial cells. J Cell Sci. 1994;107:2459-2469.
20. Robbins SG, Mixon RN, Wilson DJ, et al. Platelet-derived growth factor ligands and receptors immunolocalized in proliferative retinal diseases. Invest Ophthalmol Vis Sci. 1994;35:3649-3663.
21. Cui J, Lei H, Samad A, et al. PDGF receptors are activated in human epiretinal membranes. Exp Eye Res. 2009;88:438-444.
22. Lei H, Hovland P, Velez G, et al. A potential role for PDGF-C in experimental and clinical proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 2007;48:2335-2342.
23. Wong CA, Potter MJ, Cui JZ, et al. Induction of proliferative vitreoretinopathy by a unique line of human retinal pigment epithelial cells. Can J Ophthalmol. 2002;37:211-220.
24. Nakagawa M, Refojo MF, Marin JF, Doi M, Tolentino FI. Retinoic acid in silicone and silicone-fluorosilicone copolymer oils in a rabbit model of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci. 1995;36:2388-2395.
25. Lei H, Kazlauskas A. Growth factors outside of the platelet-derived growth factor (PDGF) family employ reactive oxygen species/Src family kinases to activate PDGF receptor alpha and thereby promote proliferation and survival of cells. J Biol Chem. 2009;284: 6329-6336.
26. Ikuno Y, Kazlauskas A. TGFβ1-dependent contraction of fibroblasts is mediated by the PDGFα receptor. Invest Ophthalmol Vis Sci. 2002;43:41-46.
27. Agrawal RN, He S, Spee C, Cui JZ, Ryan SJ, Hinton DR. In vivo models of proliferative vitreoretinopathy. Nat Protoc. 2007;2: 67-77.
28. Lei H, Velez G, Hovland P, Hirose T, Gilbertson D, Kazlauskas A. Growth factors outside the PDGF family drive experimental PVR. Invest Ophthalmol Vis Sci. 2009;50:3394-3403.
29. Lei H, Velez G, Kazlauskas A. Pathological signaling via PDGFRa involves chronic activation of Akt and suppression of p53. Mol Cell Biol. 2011;31:1788-1799.